Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 5/2011

Open Access 01-10-2011 | Original Article

The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache

Authors: Maria Antonova, Troels Wienecke, Karen Maubach, Emma Thomas, Jes Olesen, Messoud Ashina

Published in: The Journal of Headache and Pain | Issue 5/2011

Login to get access

Abstract

Using a human Prostaglandin E2 (PGE2) model of headache, we examined whether a novel potent and selective EP4 receptor antagonist, BGC20-1531, may prevent headache and dilatation of the middle cerebral (MCA) and superficial temporal artery (STA). In a three-way cross-over trial, eight healthy volunteers were randomly allocated to receive 200 and 400 mg BGC20-1531 and placebo, followed by a 25-min infusion of PGE2. We recorded headache intensity on a verbal rating scale, MCA blood flow velocity and STA diameter. There was no difference in headache response or prevention of the dilation of the MCA or the STA (P > 0.05) with either dose of BGC20-1531 relative to placebo, although putative therapeutic exposures were not reached in all volunteers. In conclusion, these data suggest that the other EP receptors may be involved in PGE2 induced headache and dilatation in normal subjects.
Literature
1.
Norel X (2007) Prostanoid receptors in the human vascular wall. Sci World J 7:1359–1374, 1:CAS:528:DC%2BD2sXhtlequ77JCrossRef
2.
Bianchi M, Martucci C, Ferrario P, Franchi S, Sacerdote P (2007) Increased tumor necrosis factor-alpha and prostaglandin E2 concentrations in the cerebrospinal fluid of rats with inflammatory hyperalgesia: the effects of analgesic drugs. Anesth Analg 104:949–954, 17377112, 10.1213/01.ane.0000258060.89380.27, 1:CAS:528:DC%2BD2sXjvVKis78%3DCrossRefPubMed
3.
Coleman RA, Smith WL, Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205–229, 7938166, 1:CAS:528:DyaK2cXlslSlsbo%3DPubMed
4.
Jadhav V, Jabre A, Lin SZ, Lee TJ (2004) EP1- and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries. J Cereb Blood Flow Metab 24:1305–1316, 15625406, 10.1097/01.WCB.0000139446.61789.14, 1:CAS:528:DC%2BD2MXjtFygCrossRefPubMed
5.
Negishi M, Sugimoto Y, Ichikawa A (1995) Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1259:109–119, 7492609CrossRefPubMed
6.
Davis RJ, Murdoch CE, Ali M, Purbrick S, Ravid R, Baxter GS et al (2004) EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 141:580–585, 14744815, 10.1038/sj.bjp.0705645, 1:CAS:528:DC%2BD2cXivVCmtbo%3DPubMedCentralCrossRefPubMed
7.
Kassuya CA, Ferreira J, Claudino RF, Calixto JB (2007) Intraplantar PGE2 causes nociceptive behaviour and mechanical allodynia: the role of prostanoid E receptors and protein kinases. Br J Pharmacol 150:727–737, 17310141, 10.1038/sj.bjp.0707149, 1:CAS:528:DC%2BD2sXjtFCqtL0%3DPubMedCentralCrossRefPubMed
8.
Smith JA, Davis CL, Burgess GM (2000) Prostaglandin E2-induced sensitization of bradykinin-evoked responses in rat dorsal root ganglion neurons is mediated by cAMP-dependent protein kinase. A Eur J Neurosci 12:3250–3258, 10.1046/j.1460-9568.2000.00218.x, 1:STN:280:DC%2BD3M%2FhslWgsQ%3D%3DCrossRef
9.
Lin CR, Amaya F, Barrett L, Wang H, Takada J, Samad TA et al (2006) Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319:1096–2103, 16966471, 10.1124/jpet.106.105569, 1:CAS:528:DC%2BD28Xht1yltL%2FPCrossRefPubMed
10.
Southall MD, Vasko MR (2001) Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 276:16083–16091, 11278900, 10.1074/jbc.M011408200, 1:CAS:528:DC%2BD3MXjvFakt70%3DCrossRefPubMed
11.
Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y et al (2007) CJ-023, 423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322:686–694, 17495127, 10.1124/jpet.107.122010, 1:CAS:528:DC%2BD2sXoslSjtbc%3DCrossRefPubMed
12.
Maubach KA, Davis RJ, Clark DE, Fenton G, Lockey PM, Clark KL et al (2009) BGC20–1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 156:316–327, 19154437, 10.1111/j.1476-5381.2009.00027.x, 1:CAS:528:DC%2BD1MXpt1Wlsr4%3DPubMedCentralCrossRefPubMed
13.
Wienecke T, Olesen J, Oturai PS, Ashina M (2009) Prostaglandin E2(PGE2) induces headache in healthy subjects. Cephalalgia 29:509–519, 19187340, 10.1111/j.1468-2982.2008.01748.x, 1:STN:280:DC%2BD1M3oslamtg%3D%3DCrossRefPubMed
14.
Iversen HK, Olesen J, Tfelt-Hansen P (1989) Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38:17–24, 2506503, 10.1016/0304-3959(89)90067-5, 1:CAS:528:DyaL1MXltlWru7o%3DCrossRefPubMed
15.
Olesen J, Steiner TJ (2004) The International classification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry 75:808–811, 15145989, 10.1136/jnnp.2003.031286, 1:STN:280:DC%2BD2c3kslGnuw%3D%3DPubMedCentralCrossRefPubMed
16.
Thomsen LL, Iversen HK (1993) Experimental and biological variation of three-dimensional transcranial Doppler measurements. J Appl Physiol 75:2805–2810, 7907324, 1:STN:280:DyaK2c7ntFKquw%3D%3DPubMed
17.
Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300:230–235, 2106931, 10.1136/bmj.300.6719.230, 1:STN:280:DyaK3c7otFKqsg%3D%3DPubMedCentralCrossRefPubMed
18.
Altman DG (1999) Practical statistics for medical research. Chapman & Hall, London, pp 455–458
19.
Busija D (2002) Prostaglandins and other Eicosanoids 2. In: Edvinsson L, Krause DN (eds) Cerebral blood flow and metabolism, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 325–338
20.
Myren M, Baun M, Ploug BK, Jansen-Olesen I, Gupta S (2010) Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine. Cephalalgia 30:1110–1122, 20713561, 10.1177/0333102409357957CrossRefPubMed
21.
Whalley ET, Schilling L, Wahl M (1989) Cerebrovascular effects of prostanoids: in-vitro studies in feline middle cerebral and basilar artery. Prostaglandins 38:625–634, 2483755, 10.1016/0090-6980(89)90045-2, 1:CAS:528:DyaK3cXntVOksQ%3D%3DCrossRefPubMed
22.
Wahl M, Schilling L, Whalley ET (1989) Cerebrovascular effects of prostanoids. In-situ studies in pial arteries of the cat. Naunyn Schmiedebergs Arch Pharmacol 340:314–320, 2812043, 10.1007/BF00168516, 1:CAS:528:DyaL1MXmt1Gru70%3DCrossRefPubMed
23.
Armstead WM (1995) Role of nitric oxide and cAMP in prostaglandin-induced pial arterial vasodilation. Am J Physiol 268:H1436–H1440, 7733344, 1:CAS:528:DyaK2MXlt1GjtL0%3DPubMed
24.
Donaldson LF, Humphrey PS, Oldfield S, Giblett S, Grubb BD (2001) Expression and regulation of prostaglandin E receptor subtype mRNAs in rat sensory ganglia and spinal cord in response to peripheral inflammation. Prostaglandins Other Lipid Mediat 63:109–122, 11204738, 10.1016/S0090-6980(00)00101-5, 1:CAS:528:DC%2BD3MXms1Wgtw%3D%3DCrossRefPubMed
25.
Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A et al (1995) In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol 116:2828–2837, 8680713, 1:CAS:528:DyaK2MXpslOhurw%3DPubMedCentralCrossRefPubMed
26.
Kumazawa T, Mizumura K, Koda H (1993) Involvement of EP3 subtype of prostaglandin E receptors in PGE2-induced enhancement of the bradykinin response of nociceptors. Brain Res 632:321–324, 8149238, 10.1016/0006-8993(93)91169-S, 1:CAS:528:DyaK2cXntVWhtg%3D%3DCrossRefPubMed
27.
Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y et al (2005) Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 1:3, 15813989, 10.1186/1744-8069-1-3PubMedCentralCrossRefPubMed
28.
Oka T, Aou S, Hori T (1994) Intracerebroventricular injection of prostaglandin E2 induces thermal hyperalgesia in rats: the possible involvement of EP3 receptors. Brain Res 663:287–292, 7874513, 10.1016/0006-8993(94)91275-0, 1:CAS:528:DyaK2cXmvFemtr0%3DCrossRefPubMed
29.
Hall A, Brown SH, Budd C, Clayton NM, Giblin GM, Goldsmith P et al (2009) Discovery of GSK345931A: an EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain. Bioorg Med Chem Lett 19:497–501, 19036582, 10.1016/j.bmcl.2008.11.032, 1:CAS:528:DC%2BD1MXmt1ajCrossRefPubMed
30.
Popp L, Haussler A, Olliges A, Nusing R, Narumiya S, Geisslinger G et al (2009) Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice. Eur J Pain 13:691–703, 18938093, 10.1016/j.ejpain.2008.09.001, 1:CAS:528:DC%2BD1MXnslyqtLw%3DCrossRefPubMed
31.
Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110, 15014183, 10.1056/NEJMoa030505, 1:CAS:528:DC%2BD2cXitV2qur0%3DCrossRefPubMed
32.
Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79:1193–1226, 10508233, 1:CAS:528:DyaK1MXmvVymtL0%3DPubMed
33.
Foudi N, Kotelevets L, Louedec L, Leseche G, Henin D, Chastre E et al (2008) Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype. Br J Pharmacol 154:1631–1639, 18516068, 10.1038/bjp.2008.214, 1:CAS:528:DC%2BD1cXps1Gru70%3DPubMedCentralCrossRefPubMed
34.
Therland KL, Stubbe J, Thiesson HC, Ottosen PD, Walter S, Sorensen GL et al (2004) Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2 EP4 receptors. J Am Soc Nephrol 15:1189–1198, 15100359, 10.1097/01.ASN.0000124673.79934.24, 1:CAS:528:DC%2BD2cXjtVCnurY%3DCrossRefPubMed
35.
Bastepe M, Ashby B (1997) The long cytoplasmic carboxyl terminus of the prostaglandin E2 receptor EP4 subtype is essential for agonist-induced desensitization. Mol Pharmacol 51:343–349, 9203641, 1:CAS:528:DyaK2sXhtlWmsLY%3DPubMed
36.
Ichikawa A, Sugimoto Y, Negishi M (1996) Molecular aspects of the structures and functions of the prostaglandin E receptors. J Lipid Mediat Cell Signal 14:83–87, 8906549, 10.1016/0929-7855(96)00512-3, 1:CAS:528:DyaK28XlvFGgtL0%3DCrossRefPubMed
37.
Regan JW (2003) EP2 and EP4 prostanoid receptor signaling. Life Sci 74:143–153, 14607241, 10.1016/j.lfs.2003.09.031, 1:CAS:528:DC%2BD3sXos12qtro%3DCrossRefPubMed
38.
Desai S, April H, Nwaneshiudu C, Ashby B (2000) Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. Mol Pharmacol 58:1279–1286, 11093764, 1:CAS:528:DC%2BD3cXovFeqsrw%3DPubMed
39.
Nishigaki N, Negishi M, Ichikawa A (1996) Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol Pharmacol 50:1031–1037, 8863851, 1:CAS:528:DyaK28XmsFGnsr8%3DPubMed
40.
Tai HH, Ensor CM, Tong M, Zhou H, Yan F (2002) Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 68–69:483–493, 12432938, 10.1016/S0090-6980(02)00050-3CrossRefPubMed
41.
Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J (2005) BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77:202–213, 15735614, 10.1016/j.clpt.2004.10.001, 1:CAS:528:DC%2BD2MXhsVyrs7Y%3DCrossRefPubMed
Metadata
Title
The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headache
Authors
Maria Antonova
Troels Wienecke
Karen Maubach
Emma Thomas
Jes Olesen
Messoud Ashina
Publication date
01-10-2011
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 5/2011
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1007/s10194-011-0358-9

Other articles of this Issue 5/2011

The Journal of Headache and Pain 5/2011 Go to the issue

Announcement

Announcement

Original

Epicrania fugax with backward radiation: clinical characteristics of nine new cases

Letter to the Editor

“Comorbidity” between epilepsy and headache/migraine: the other side of the same coin!

Brief Report

Pulsed radiofrequency of the second cervical ganglion (C2) for the treatment of cervicogenic headache

Original

Classification and clinical features of headache patients: an outpatient clinic study from China

Original Article

The Eurolight project: the impact of primary headache disorders in Europe. Description of methods